Nov 30, 2020 11:16 JST

Source: Eisai

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of alpha-synuclein misfolding and aggregation

TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Wren Therapeutics Ltd. today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target alpha-synuclein for the potential treatment of synucleinopathies including Parkinson's disease and dementia with Lewy bodies.

Wren possesses a novel network kinetics drug discovery platform that precisely quantifies the effects of small molecules on the protein misfolding and aggregation pathway that causes neurodegenerative diseases. Wren's approach to synucleinopathies is focused on identifying novel small molecules that selectively control the aggregation process of alpha-synuclein, which is associated with the onset and progression of these diseases. The collaboration will use Wren's network kinetics drug discovery platform, alongside Eisai's extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.

Dr. Samuel Cohen, Chief Executive Officer of Wren, commented: "We are delighted to have formed this collaboration with Eisai, a company with a distinguished track record and company-wide commitment to providing innovative treatments for patients suffering from neurodegenerative diseases. We believe that by combining our unique, predictive and quantitatively driven platform with Eisai's deep expertise in neurology, we can together advance highly differentiated small molecules targeting alpha-synuclein for the treatment of debilitating protein misfolding disorders such as Parkinson's disease."

Dr. Teiji Kimura, Vice President, Chief Discovery Officer of the Eisai Neurology Business Group, commented: "Synucleinopathies such as dementia with Lewy bodies and Parkinson's disease represent a significant unmet medical need due to the lack of any effective disease-modifying treatments. The accumulation of alpha-synuclein oligomers with protein misfolding is an important hallmark of these diseases. The Wren team, with its world-renowned founding scientists, is pioneering a new and fundamentally different approach to addressing protein misfolding diseases. By integrating capabilities across both companies we expect this exciting collaboration to be uniquely successful in identifying novel disease-modifying therapeutics for patients suffering from dementia with Lewy bodies, Parkinson's disease and related disorders."

About Wren's novel network kinetics drug discovery platform

Wren's proprietary network kinetics drug discovery platform enables an entirely new approach to drug discovery, designed specifically to address the unique challenges associated with protein misfolding diseases. The kinetics-based approach solves for the distinct molecular reaction network that underlies each misfolding disease and produces a fully predictive, quantitative map of the network and its dynamics. The platform identifies the optimum intervention points in the network to reduce the populations of toxic misfolded and aggregated species, and subsequently makes it possible to identify and optimise molecules with the desired kinetics inhibitory activity.

About Synucleinopathies

Synucleinopathies are neurodegenerative diseases characterised by the aberrant misfolding and aggregation of alpha-synuclein in neurons and glial cells. Synucleinopathies include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).

About Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For further information on Eisai Co., Ltd., please visit https://www.eisai.com.

About Wren Therapeutics Ltd.

Wren is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden), focused on drug discovery and development for protein misfolding diseases. Wren is advancing an entirely novel approach to address this class of diseases, based on more than a decade of research from its scientific founders focused on the chemical kinetics of the protein misfolding process. Wren's predictive, quantitative platform is built on concepts from the physical sciences and is a fundamental shift from the descriptive, qualitative methods of traditional biology, which have failed to successfully address these complex systems. Wren is using its unique approach to develop a broad pipeline of therapeutics for protein misfolding diseases.

For further information on Wren, please visit www.wrentherapeutics.com

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
 
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
 
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
March 31 2021 20:22 JST
 
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
March 31 2021 20:18 JST
 
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
March 30 2021 11:42 JST
 
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
March 26 2021 08:16 JST
 
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
March 23 2021 17:34 JST
 
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
March 22 2021 12:13 JST
 
Eisai Awarded The New Diversity Management Selection 100
March 22 2021 09:38 JST
 
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders
March 17 2021 10:05 JST
 
More Press release >>

Latest Press Release


More Latest Release >>